INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Embracing the Power of Data Analytics and AI for Clinical Trials

Guillaume Gigon

Guillaume Gigon

Vice-President, Technology and AI

Author picture

Embracing the Power of Data Analytics and AI for Clinical Trials
Indero’s expertise is showcased in the article “Embracing the Power of Data Analytics and AI for Clinical Trials” by News-Medical. The article covers:

  • The increasing adoption of digital systems in clinical trials.
  • The article highlights the integration of artificial intelligence and machine learning to enhance data management, streamline operations, and ensure high-quality results.
  • It discusses the importance of real-time data access for prompt decision-making and the challenges of incorporating evolving digital platforms.

For a detailed look at how these technologies are transforming clinical trials, read the full article here:
  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >